We are a global biopharmaceutical company with a steadfast commitment to developing innovative medicines for central nervous system (CNS) diseases with unmet needs.
At the center of our drug development process is a keen focus on how new medicines can be designed to meet the real-world needs of patients, physicians and payers. We ask the important questions up front about how a new medicine can be best designed, how outcomes can be improved, and how there can be a strong economic, as well as medical, rationale for a new drug product. We believe that when drug development begins with real world and human questions like these, it leads to innovative products that can truly help patients and physicians better manage diseases.
Our patient-inspired approach to drug development has led us to create a rich pipeline of proprietary drug candidates in development for major CNS disease areas, such as schizophrenia, major depressive disorder and multiple sclerosis. Advancing new CNS treatments is a vital endeavor for millions of patients and their families, for the multitude of dedicated healthcare providers, and for the potential impact on costs to our society. While these novel product candidates in our pipeline are fueling our future growth, we have a strong financial foundation from our diversified product portfolio that represents our proven expertise and our proprietary technologies.
We are in an exciting phase of growth that few biotechnology companies achieve, with our diversified portfolio of commercial products and an exciting late-stage pipeline. We are moving ahead with global capabilities, an established approach to innovation, world-class manufacturing, financial strength, and our experienced and dedicated people. We couldn’t be more enthusiastic and optimistic about the future growth of Alkermes.
We welcome your interest in our company.